Patent · US Active

Nucleic acid encoding anti-GM-CSF antibodies

US11028165B2 · kind B2 · utility

0Cited by

6References

14Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Stefan Steidl · Munich, DE
Elisabeth Thomassen-Wolf · Birkenfeld, DE

Key dates

Filing date	Jun 17, 2019
Grant date	Jun 8, 2021
Priority date	—
Expiry date	Jun 17, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.